Real-world insights on comparative effectiveness of mRNA COVID-19 boosters | Multidisciplinary

Two target trials were emulated to compare the effectiveness of third doses of mRNA-based COVID-19 vaccines among US veteran population and across at-risk US veteran populations.

Among the average-risk population and the age >65 subgroup, both mRNA-1273 and BNT162b2 were equally effective with no difference between COVID-19 outcomes.

However, subgroup analysis results suggest that high-risk individuals with high-risk comorbid or immunocompromising conditions will benefit more from 3 doses of mRNA-1273 vaccine over BNT162b2 vaccine.

Resources

Real-world insights on comparative effectiveness of mRNA COVID-19 boosters